The invention relates to an antitumour pharmaceutical combination comprising ombrabulin or AVE8062, which may be in the form of a base or in the form of a pharmaceutically acceptable salt, and cetuximab, for use thereof as an antitumour agent intended for patients who are also treated with radiotherapy, in particular suffering from cancers and even more particularly suffering from solid tumours.本發明係關於一種包含可呈鹼形式或呈醫藥上可接受之鹽形式之奧瑞布林(ombrabulin)或AVE8062及西妥昔單抗(cetuximab)之抗腫瘤醫藥組合,其係作為抗腫瘤劑,用於亦使用放射線治療(特定言之,罹患癌症,及甚至更特定言之,罹患實體腫瘤)之患者。
